Align Technology, Inc. vs Vanguard Real Estate Index Fund ETF — how do they compare? Align Technology, Inc. trades at $179.9 (market cap $12.86B), while Vanguard Real Estate Index Fund ETF trades at $97.41. The key difference: Vanguard Real Estate Index Fund ETF is trading nearer its 52-week high, Align Technology, Inc. nearer its low. Which is the better fit depends on your goals.
| ALGN | VNQ | |
|---|---|---|
Market Cap | $12.86B | — |
Sector | Health | — |
52-Week High | $207.19 | $98.66 |
52-Week Low | $124.88 | $87.00 |
Enterprise Value | $11.92B | — |
Signals from Pluang's Aura AI — not financial advice
Align Technology (ALGN) trades at $179.45, up 0.72% with a bullish technical outlook from moving averages. The company maintains solid profitability with a 10.5% net margin and has beaten EPS estimates for three consecutive quarters. Recent developments include a new manufacturing facility in India and upcoming Q2 2026 earnings on July 29, 2026.
ALGN offers growth potential with a consensus price target of $218.40, representing 22% upside, supported by 73% analyst buy ratings. Risks include European regulatory scrutiny and North American demand pressures. The stock's valuation at 30x P/E requires sustained earnings growth to justify further gains.
VNQ trades at $97.32, up 0.24% with a bullish technical signal from moving averages. The ETF shows neutral momentum oscillators with RSI at 56.24, while recent news highlights REIT sector resilience amid interest rate pressures. Support levels cluster around $96-97 with resistance at $98.
The REIT ETF faces headwinds from elevated interest rates but benefits from steady dividend income and sector recovery signs. Key risks include Fed policy uncertainty and inflation persistence, while institutional sentiment remains cautiously optimistic about real estate fundamentals.
Trailing returns across standard periods
Latest headlines on both assets
Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).
Read more on ALGN →The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →